|
TIDMPHRM
RNS Number : 7593D
Phorm Inc
22 May 2012
22 May 2012
Phorm, Inc. ('Phorm' or 'the Company')
Phorm Announces AGM Notice and Proposed Board Change
AGM Notice
Phorm (AIM: PHRM and PHRX), today announces that it will hold its Annual General Meeting ("AGM") at 11.00 am on 19 June 2012 at Liberty House, 222 Regent Street, London, W1B 5TR.
The notice and proxy statement outlining details of the AGM has today been posted to shareholders and a copy of the same will be available on the investor relations section of the Phorm website (www.phorm.com).
Proposed Board Change
At the AGM it is proposed that Christopher Delorme be elected as a non-executive director of the Company and that Andrew Croxson be elected as an executive director of the Company.
Mr Delorme is a partner in RSR CAPITAL PTE LTD, a Singapore based investment fund. He has been in Asia for 20 years, having spent 17 years in Japan as an equity derivatives broker for FIMAT, a subsidiary of Societe Generale North Pacific in Tokyo. From 1995, he developed OTC (over the counter) functions for brokerage firms including Tullett and ICAP. He then returned to FIMAT in 2003 where he established them as the leading broker in OTC derivatives in Asia. He holds a BA degree from Ecole des Cadres in Paris and is fluent in French and English. Should Mr Delorme be elected at the AGM further disclosure will be made in accordance with the AIM Rules of the London Stock Exchange.
Andrew Croxson, Phorm's Chief Financial Officer and Chief Operating Officer, has responsibility for global finance and operations at Phorm and has been with the Company for over 3 years. Andrew has over 12 years experience working in the Technology, Media and Telecommunications ("TMT") sector. Andrew was previously Managing Director of TMT specialists Ingenious Consulting. Prior to that, he was a partner at Spectrum Strategy Consultants leading its technology practice worldwide. Andrew is an ACA qualified chartered accountant and has Masters Degrees from both Oxford and Cambridge Universities. As well as Andrew's significant financial knowledge, he also brings deep experience of advising brand leading media and technology companies and strategic insights into building and scaling global operations. Should Mr Croxson be elected at the AGM further disclosure will be made in accordance with the AIM Rules of the London Stock Exchange.
Stephen Partridge-Hicks' term of office comes to an end at the AGM.
Operationally the Company continues to make progress on all matters referred to last October and will update the market when appropriate.
For Enquiries
Phorm, Inc.
Mark Williams (analysts & investors) +44 20 7297 2326
Alex Laity (media) +44 20 7297 2710
Liberum Capital +44 20 3100 2222
(Nominated Advisor and Joint Broker)
Chris Bowman and Richard Bootle
Mirabaud Securities LLP +44 20 7321 2508
(Joint Broker)
Jason Woollard
Peter Krens
- ends -
About Phorm
Phorm is a global personalisation technology company that makes content and advertising more relevant to the consumer. Phorm's innovative platform preserves user privacy and delivers a more interesting online experience.
Phorm's partners include leading Internet Service Providers (ISPs), Publishers, Ad Networks and Advertisers.
A Delaware, US incorporated company, Phorm was admitted to the AIM market of the London Stock Exchange in 2004 and has over 140 employees and contractors.
For more information, please visit: www.phorm.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOAEAFSFADDAEFF
| 
